- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 270 of 2,219.
| EudraCT Number: 2020-000165-16 | Sponsor Protocol Number: DC2019REGROUP01 | Start Date*: 2020-09-16 |
| Sponsor Name:Amsterdam University Medical Center - location VU Medical Center | ||
| Full Title: A single-center, prospective, placebo-controlled, double-blind, randomized, cross-over mechanistic intervention study to investigate the effect of empagliflozin on kidney function in people with ei... | ||
| Medical condition: Diabetes Mellitus type 2 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-000270-36 | Sponsor Protocol Number: AbiCab | Start Date*: 2015-05-07 | |||||||||||
| Sponsor Name:Umeå University Hospital | |||||||||||||
| Full Title: A randomized Phase II, open label multicenter cross-over study, to evaluate biomarkers, in 2nd line treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) with abiraterone and cabazit... | |||||||||||||
| Medical condition: Metastatic Castration Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000435-33 | Sponsor Protocol Number: NP25737 | Start Date*: 2015-08-07 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A phase I pharmacokinetic and safety study of tocilizumab (TCZ) in patients less than 2 years old with active systemic juvenile idiopathic arthritis (sJIA) | |||||||||||||
| Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) BE (Completed) ES (Completed) PL (Completed) GB (Completed) FR (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003048-11 | Sponsor Protocol Number: GIPIT002 | Start Date*: 2014-10-24 |
| Sponsor Name:GIPIT | ||
| Full Title: FEcal transplant, a Dazzling debut to Eradicate colonization with eXtreme drug resistant bacteria? | ||
| Medical condition: Patient harboring Extreme Drug Resistant (XDR) bacteria. Our trial try to eradicate this digestive tract colonization by performing a fecal transplantation. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-004790-32 | Sponsor Protocol Number: 204836 | Start Date*: 2016-03-07 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
| Full Title: A 29-day, randomized, double-blinded, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of GSK1278863 in hemo... | |||||||||||||
| Medical condition: Anemia associated with chronic kidney disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-005628-25 | Sponsor Protocol Number: Td540 | Start Date*: 2016-01-13 | |||||||||||||||||||||
| Sponsor Name:Sanofi-Aventis K.K. | |||||||||||||||||||||||
| Full Title: Immunogenicity and Safety of The tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (SP306) as a Booster in Japanese Adolescents | |||||||||||||||||||||||
| Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2015-003914-25 | Sponsor Protocol Number: Td527 | Start Date*: 2016-01-13 | |||||||||||||||||||||
| Sponsor Name:SANOFI PASTEUR | |||||||||||||||||||||||
| Full Title: Clinical Safety Study of the Tdap Combined Vaccine (ADACEL) as a Booster Dose in Healthy Adults and Children in China | |||||||||||||||||||||||
| Medical condition: Active immunization against tetanus, diphtheria and pertussis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2015-003491-69 | Sponsor Protocol Number: CACZ885DCA01 | Start Date*: 2016-04-14 | |||||||||||
| Sponsor Name:Novartis Pharmaceuticals | |||||||||||||
| Full Title: An Open Label Study to Assess the Safety, Tolerability and Efficacy of Canakinumab (ACZ885) in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada | |||||||||||||
| Medical condition: Cryopyrin Associated Periodic Syndrome | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002045-36 | Sponsor Protocol Number: | Start Date*: 2016-11-17 |
| Sponsor Name:University of Oxford, Clinical Trials and Research Governance | ||
| Full Title: Lifestyle induced weight loss and Liraglutide in the treatment of non-alcoholic steatohepatitis (NASH) | ||
| Medical condition: Non-alcoholic steatohepatitis (NASH) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-003216-28 | Sponsor Protocol Number: A6531002 | Start Date*: 2020-09-10 |
| Sponsor Name:Pfizer, Inc. | ||
| Full Title: A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP PILOT STUDY TO EVALUATE THE EFFICACY OF DEXTROMETHORPHAN HYDROBROMIDE ON ACUTE COUGH IN A PEDIATRIC POPULATION | ||
| Medical condition: cough | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2014-002948-40 | Sponsor Protocol Number: GEM-CESAR | Start Date*: 2015-03-03 | |||||||||||
| Sponsor Name:Fundación PETHEMA | |||||||||||||
| Full Title: A phase II multicenter study of carfilzomib, lenalidomide and dexamethasone (KRd) plus high-dose therapy with melphalan-200 and autologous stem cell transplantation, followed by consolidation with ... | |||||||||||||
| Medical condition: Smoldering multiple myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-004587-38 | Sponsor Protocol Number: ESKETINTRD3004 | Start Date*: 2015-08-05 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression | |||||||||||||
| Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Completed) DE (Completed) ES (Completed) GB (Completed) AT (Completed) PL (Completed) BG (Completed) LT (Completed) FI (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002142-31 | Sponsor Protocol Number: 547-SSE-301 | Start Date*: 2016-11-16 | |||||||||||
| Sponsor Name:Sage Therapeutics | |||||||||||||
| Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS | |||||||||||||
| Medical condition: SUPER-REFRACTORY STATUS EPILEPTICUS (SRSE) | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) SE (Completed) DK (Completed) ES (Completed) NL (Completed) FI (Completed) HU (Completed) AT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-002078-19 | Sponsor Protocol Number: AC-055-405 | Start Date*: 2015-10-14 | |||||||||||
| Sponsor Name:ACTELION Pharmaceuticals France | |||||||||||||
| Full Title: Prospective, multicenter, open-label study evaluating the effects of first-line oral combination therapy of macitentan and tadalafil in patients with newly diagnosed pulmonary arterial hypertension. | |||||||||||||
| Medical condition: Pulmonary arterial hypertension | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004224-59 | Sponsor Protocol Number: MK-0431-848 | Start Date*: 2016-07-27 |
| Sponsor Name:Merck Sharp & Dohme Corp. | ||
| Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Met... | ||
| Medical condition: Type 2 Diabetes mellitus | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-005285-38 | Sponsor Protocol Number: IM101-591 | Start Date*: 2020-01-14 | |||||||||||
| Sponsor Name:The University of Leeds | |||||||||||||
| Full Title: Phase II proof of concept study of Abatacept (Orencia) in individuals who aRe Considered At risk of Developing Inflammatory Arthritis | |||||||||||||
| Medical condition: Inflammatory arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001534-13 | Sponsor Protocol Number: JAN13004-30 | Start Date*: 2015-10-02 | |||||||||||
| Sponsor Name:SPHERIUM BIOMED S.L. | |||||||||||||
| Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation. | |||||||||||||
| Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-004451-40 | Sponsor Protocol Number: H15/02 | Start Date*: 2016-02-17 | |||||||||||
| Sponsor Name:Almirall Hermal GmbH | |||||||||||||
| Full Title: SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICS THE S A V A N T TRIAL | |||||||||||||
| Medical condition: Moderate to severe spasticity due to MS (multiple sclerosis). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001049-10 | Sponsor Protocol Number: M14-726 | Start Date*: 2015-09-24 | |||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
| Full Title: Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir with Ribavirin (RBV) in Adult Patients with GT1 or GT4 Chronic HCV Infection and Re... | |||||||||||||
| Medical condition: Chronic Hepatitis C Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001580-39 | Sponsor Protocol Number: C38072-AS-30027 | Start Date*: 2015-10-30 | |||||||||||
| Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
| Full Title: A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 weeks) in Patients with Oral Corticosteroid Dependen... | |||||||||||||
| Medical condition: Asthma & elevated blood Eosinophils | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) BE (Completed) ES (Completed) IT (Completed) NL (Completed) PL (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.